From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q3 2022 call → NOWe need to determine if management describes a recent transition into an approved/listed/qualified status within buyers' systems, such that future business can arrive without discrete selling events, and that this is new enough that most volume is still ahead. Scan the transcript for relevant statements. Management discusses market share, product launches, distribution expansions, international shipments, and capacity. They mention "expanded distribution" of Tremblant hash to 5 provinces, achieving full distribution. They mention SHRED products now available in all provinces. They mention being in a #3 position, etc. But is there any mention of being added to a formulary, approved supplier list, procurement program, or similar? The closest is "distribution" and "planograms" with provincial boards. For example, they mention "increased distribution" and "planograms" with SQDC. But is that a formal listing? They talk about "relationships with provincial boards" and "planograms" - that is essentially being listed in the provincial cannabis stores' catalogs. However, is that a recent transition? They say "we have had some conversations there. And we've equally, with the acquisition of Laurentian, have been able to build that relationship with SQDC as well and have seen some planned increases in our planograms." That suggests they are getting more shelf space, but it's not a new status that eliminates selling effort. They also mention "we are now selling SHRED in all of our provinces" - that is distribution expansion, but each order still requires selling? Actually, in cannabis, being listed in a provincial store's catalog is a form of listing, but it's not like a formulary where purchases are automatic. The question asks about "approved, specified, listed, qualified, registered, reimbursed, or pre-authorized choice inside buyers' own purchasing, reimbursement, formulary, specification, procurement, network, catalog, or program systems" - a catalog listing could count. But is it new? They say they expanded distribution to all provinces, which is recent.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.